Amarillo Biosciences

Dec 03, 04
06:00 ET	Amarillo Biosciences Issues Report to Shareholders
Sep 14, 04
10:19 ET	Amarillo Biosciences Licenses Low-Dose Oral Interferon Rights to NOBEL to Treat Behcet's Disease
Sep 09, 04
06:00 ET	Amarillo Biosciences Requests Designated New Animal Drug Listing for Ten Diseases From FDA's Office of Minor Use and Minor Species Animal Drug Development (MUMS)
Jul 22, 04
12:13 ET	Japanese Regulatory Approval Granted for Oral Interferon Treatment of Rotavirus in Cattle
Jun 24, 04
11:06 ET	Amarillo Biosciences (ABI) President Dr. Joseph M. Cummins to Address Japan Interferon Cytokine Research Conference in July 2004 to Discuss ABI's Development Plans for Oral Interferon Therapies in Animal and Human Health
Apr 26, 04
14:41 ET	BBC Interviews Amarillo Biosciences President & CEO Dr. Joseph M. Cummins About Foot and Mouth Disease
Nov 18, 03
16:08 ET	Amarillo Biosciences' Maxisal(R) Receives Regulatory Approval for Korea
Oct 14, 03
10:01 ET	Amarillo Biosciences Files Investigational New Drug (IND) Application to Test Oral Interferon Alpha in Oral Warts in HIV-Positive Subjects
Sep 30, 03
17:51 ET	Amarillo Biosciences Names Members of Committee to Develop an Alternative To Depopulation (CDAD)
Sep 04, 03
09:30 ET	Amarillo Biosciences Forms Research Committee to Counter Foreign Animal Diseases
Aug 22, 03
16:02 ET	Amarillo Biosciences Supports a Campaign to Protect Livestock Against Agro- Terror Attacks
Jun 02, 03
13:37 ET	Amarillo Biosciences Joins Asia's War on SARS
Sep 03, 02
12:28 ET	Amarillo Biosciences, Inc. Signs Option Agreement; 'Would You Like Interferon With That?'
Jul 15, 02
10:59 ET	Amarillo Biosciences, Inc. Licenses Rights to Low Dose Oral Interferon For Hepatitis B in 40 African Countries; and Executes Dietary Supplement Agreement For Korea
Jun 11, 02
08:02 ET	Amarillo Biosciences, Inc. Enters Supply Agreements in Taiwan, China And Pakistan for Sale of Nutraceutical
Feb 05, 02
08:03 ET	Amarillo Biosciences to Receive Patent on Solid Dosage Forms of Interferon; Company Also Obtains Additional Funding Through Private Placement
Nov 07, 01
09:30 ET	Amarillo Biosciences's Orally-Administered Interferon Alpha to Be Tested As Treatment for Idiopathic Pulmonary Fibrosis Under Grant Awarded to Texas Tech University Health Sciences Center
Oct 23, 01
09:30 ET	Amarillo Biosciences, Inc.'s Supply Agreement With Natrol, Inc. Lands Them In Nationally Recognized Pharmacy
Oct 16, 01
12:15 ET	Amarillo Biosciences, Inc. Receives SBIR Grant to Develop Vaccine For Helicobacter Pylori
Oct 02, 01
09:15 ET	Amarillo Biosciences, Inc. Licenses Rights to Low Dose Oral Interferon For Orphan Drug Indications
Jul 17, 01
10:43 ET	Amarillo Biosciences, Inc. Announces Supplemental Analysis of Phase II Fibromyalgia Syndrome Clinical Trial
Jan 05, 01
10:48 ET	Amarillo Biosciences, Inc. Announces Completion of Phase III Sjogren's Syndrome Clinical Trial
Dec 14, 00
12:59 ET	Nutraceutical: Amarillo Biosciences, Inc. Announces Exclusive Supply Agreement With Natrol, Inc. for SALIVE(TM)
Nov 07, 00
07:00 ET	Amarillo Biosciences Engages Hunter Wise Financial Group to Explore Shareholder Value Options
Aug 22, 00
08:05 ET	Orphan Drug Designation Received
Aug 01, 00
10:35 ET	Amarillo Biosciences Engages Investment Banking Firm
Jun 15, 00
12:05 ET	Interferon Gamma: Amarillo Biosciences, Inc. and Hayashibara Biochemical Laboratories Broaden Scope of Interferon Gamma Agreement
May 22, 00
11:53 ET	Amarillo Biosciences, Inc. Announces Plans for Entry into the Natural Products Market Place
May 16, 00
12:07 ET	Hepatitis C: Amarillo Biosciences, Inc. and Biopharm Group International Execute Collaboration Agreement
May 15, 00
10:31 ET	Amarillo Biosciences Announces South African Licensing Agreement
Apr 07, 00
08:05 ET	Amarillo Biosciences, Inc. Announces Results From Phase III Study Of Interferon Alpha in Sjogren's Syndrome
Apr 04, 00
14:41 ET	Amarillo Biosciences, Inc. Announces Agreement Regarding Interferon Gamma With Molecular Medicine Research Institute
Mar 09, 00
08:05 ET	Amarillo Biosciences, Inc. Announces Results of Fibromyalgia Syndrome Phase II Trial
Feb 01, 00
08:05 ET	Amarillo Biosciences Announces Oral Interferon-Alpha Granted Orphan Drug Designation for Behcet's Disease
Oct 13, 99
12:19 ET	Amarillo Biosciences Announces Delisting From Nasdaq
Sep 30, 99
11:47 ET	Amarillo Biosciences Announces Common Stock Sale to Japanese Partners
Aug 26, 99
09:02 ET	Oral Use of Interferons and Cytokines Highlighted, Reports Amarillo Biosciences, Inc.
Jul 19, 99
09:47 ET	Amarillo Biosciences Announces Loan Agreement With Hayashibara Biochemical Laboratories (HBL)
Jun 16, 99
11:37 ET	Amarillo Biosciences, Inc. (ABI) and North China Pharmaceutical Corporation (NCPC) Agree to Jointly Develop Interferon-alpha Lozenges for the Treatment of Hepatitis B in China
Apr 28, 99
10:03 ET	Amarillo Biosciences Expands Phase II Clinical Trial in Treatment in Fibromyalgia
Apr 14, 99
10:20 ET	Mr. Richard Franco and Dr. Edward Amento are New Candidates for the Board of Directors of Amarillo Biosciences, Inc.
Apr 07, 99
09:42 ET	Dr. Philip C. Fox, Director of Research & Development, Amarillo Biosciences, Inc. to Deliver Broadhurst Distinguished Lecture
Apr 06, 99
09:40 ET	Amarillo Biosciences Announces Expansion of Phase 3 Clinical Trial
Apr 05, 99
09:42 ET	Amarillo Biosciences Announces Debt Converted to Common Stock
Mar 09, 99
12:59 ET	Amarillo Biosciences Announces That Newly Published Research Supports Oral Interferon Efficacy and Safety
Jan 04, 99
08:02 ET	Amarillo Biosciences Appoints Chief Operating Officer